More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond
Prostate cancer is the second most common cancer type in men globally. Although the prognosis for localized prostate cancer is good, no curative treatments are available for metastatic disease. Better diagnostic methods could help target therapies and improve the outcome. Prostate-specific membrane...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/9/2244 |
| _version_ | 1797535015909720064 |
|---|---|
| author | Anniina Hyväkkä Verneri Virtanen Jukka Kemppainen Tove J. Grönroos Heikki Minn Maria Sundvall |
| author_facet | Anniina Hyväkkä Verneri Virtanen Jukka Kemppainen Tove J. Grönroos Heikki Minn Maria Sundvall |
| author_sort | Anniina Hyväkkä |
| collection | DOAJ |
| description | Prostate cancer is the second most common cancer type in men globally. Although the prognosis for localized prostate cancer is good, no curative treatments are available for metastatic disease. Better diagnostic methods could help target therapies and improve the outcome. Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed on malignant prostate tumor cells and correlates with the aggressiveness of the disease. PSMA is a clinically validated target for positron emission tomography (PET) imaging-based diagnostics in prostate cancer, and during recent years several therapeutics have been developed based on PSMA expression and activity. The expression of PSMA in prostate cancer can be very heterogeneous and some metastases are negative for PSMA. Determinants that dictate clinical responses to PSMA-targeting therapeutics are not well known. Moreover, it is not clear how to manipulate PSMA expression for therapeutic purposes and develop rational treatment combinations. A deeper understanding of the biology behind the use of PSMA would help the development of theranostics with radiolabeled compounds and other PSMA-based therapeutic approaches. Along with PSMA several other targets have also been evaluated or are currently under investigation in preclinical or clinical settings in prostate cancer. Here we critically elaborate the biology and scientific rationale behind the use of PSMA and other targets in the detection and therapeutic targeting of metastatic prostate cancer. |
| first_indexed | 2024-03-10T11:38:37Z |
| format | Article |
| id | doaj.art-7320b827af894b30b132ff55282e8551 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T11:38:37Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-7320b827af894b30b132ff55282e85512023-11-21T18:40:30ZengMDPI AGCancers2072-66942021-05-01139224410.3390/cancers13092244More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and BeyondAnniina Hyväkkä0Verneri Virtanen1Jukka Kemppainen2Tove J. Grönroos3Heikki Minn4Maria Sundvall5Institute of Biomedicine, Cancer Research Unit, FICAN West Cancer Center Laboratory, University of Turku and Turku University Hospital, FI-20520 Turku, FinlandInstitute of Biomedicine, Cancer Research Unit, FICAN West Cancer Center Laboratory, University of Turku and Turku University Hospital, FI-20520 Turku, FinlandTurku PET Centre, University of Turku, FI-20521 Turku, FinlandPreclinical Imaging Laboratory, Turku PET Centre, University of Turku, FI-20520 Turku, FinlandDepartment of Oncology, FICAN West Cancer Center, University of Turku and Turku University Hospital, FI-20521 Turku, FinlandInstitute of Biomedicine, Cancer Research Unit, FICAN West Cancer Center Laboratory, University of Turku and Turku University Hospital, FI-20520 Turku, FinlandProstate cancer is the second most common cancer type in men globally. Although the prognosis for localized prostate cancer is good, no curative treatments are available for metastatic disease. Better diagnostic methods could help target therapies and improve the outcome. Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein that is overexpressed on malignant prostate tumor cells and correlates with the aggressiveness of the disease. PSMA is a clinically validated target for positron emission tomography (PET) imaging-based diagnostics in prostate cancer, and during recent years several therapeutics have been developed based on PSMA expression and activity. The expression of PSMA in prostate cancer can be very heterogeneous and some metastases are negative for PSMA. Determinants that dictate clinical responses to PSMA-targeting therapeutics are not well known. Moreover, it is not clear how to manipulate PSMA expression for therapeutic purposes and develop rational treatment combinations. A deeper understanding of the biology behind the use of PSMA would help the development of theranostics with radiolabeled compounds and other PSMA-based therapeutic approaches. Along with PSMA several other targets have also been evaluated or are currently under investigation in preclinical or clinical settings in prostate cancer. Here we critically elaborate the biology and scientific rationale behind the use of PSMA and other targets in the detection and therapeutic targeting of metastatic prostate cancer.https://www.mdpi.com/2072-6694/13/9/2244castration resistant prostate cancer (CRPC)molecular imagingpositron emission tomography (PET)prostate-specific membrane antigen (PSMA)radionuclide therapytherapeutic antibodies |
| spellingShingle | Anniina Hyväkkä Verneri Virtanen Jukka Kemppainen Tove J. Grönroos Heikki Minn Maria Sundvall More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond Cancers castration resistant prostate cancer (CRPC) molecular imaging positron emission tomography (PET) prostate-specific membrane antigen (PSMA) radionuclide therapy therapeutic antibodies |
| title | More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond |
| title_full | More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond |
| title_fullStr | More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond |
| title_full_unstemmed | More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond |
| title_short | More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond |
| title_sort | more than meets the eye scientific rationale behind molecular imaging and therapeutic targeting of prostate specific membrane antigen psma in metastatic prostate cancer and beyond |
| topic | castration resistant prostate cancer (CRPC) molecular imaging positron emission tomography (PET) prostate-specific membrane antigen (PSMA) radionuclide therapy therapeutic antibodies |
| url | https://www.mdpi.com/2072-6694/13/9/2244 |
| work_keys_str_mv | AT anniinahyvakka morethanmeetstheeyescientificrationalebehindmolecularimagingandtherapeutictargetingofprostatespecificmembraneantigenpsmainmetastaticprostatecancerandbeyond AT vernerivirtanen morethanmeetstheeyescientificrationalebehindmolecularimagingandtherapeutictargetingofprostatespecificmembraneantigenpsmainmetastaticprostatecancerandbeyond AT jukkakemppainen morethanmeetstheeyescientificrationalebehindmolecularimagingandtherapeutictargetingofprostatespecificmembraneantigenpsmainmetastaticprostatecancerandbeyond AT tovejgronroos morethanmeetstheeyescientificrationalebehindmolecularimagingandtherapeutictargetingofprostatespecificmembraneantigenpsmainmetastaticprostatecancerandbeyond AT heikkiminn morethanmeetstheeyescientificrationalebehindmolecularimagingandtherapeutictargetingofprostatespecificmembraneantigenpsmainmetastaticprostatecancerandbeyond AT mariasundvall morethanmeetstheeyescientificrationalebehindmolecularimagingandtherapeutictargetingofprostatespecificmembraneantigenpsmainmetastaticprostatecancerandbeyond |